申请人:Eisenbrand Gerhard
公开号:US20050054653A1
公开(公告)日:2005-03-10
Compounds of the general formula (I) and their acid addition salts are provided
wherein:
R
1
signifies a piperazino, p-phenylenediamino, a 2,5-diazabicyclo-[2.2.1]-heptane, a 2,5-diazabicyclo-[2.2.2]-octane radical or a 3,8-diazabicyclo-[3.2.1]-octane radical, which in each case can be substituted with at least one substituent,
R
2
, R
4
, which are in each case the same, signify a pyrrolidino, thiazolidino, oxazolidino or imidazolidino radical, which in each case can be substituted with at least one substituent, and
R
3
signifies an alkyl, alkoxy, alkylmercapto or an alkylamino radical, which in each case can be substituted with at least one substituent. These pteridine derivatives are suitable for the inhibition of phosphodiesterases and therefore for the prophylaxis and/or treatment of thrombo-embolic, neurodegenerative diseases, inflammatory diseases, asthmatic diseases as well as hemato-oncological diseases.
提供通式(I)的化合物及其酸加成盐
其中
R
1
表示哌嗪基、对苯二胺基、2,5-二氮杂双环-[2.2.1]-庚烷基、2,5-二氮杂双环-[2.2.2]-辛烷基或 3,8-二氮杂双环-[3.2.1]-辛烷基,在每种情况下,它们可被至少一个取代基取代、
R
2
, R
4
表示吡咯烷基、噻唑烷基、噁唑烷基或咪唑烷基,它们在每种情况下均可被至少一个取代基取代,以及
R
3
表示烷基、烷氧基、烷基巯基或烷基氨基,在每种情况下至少可被一个取代基取代。这些蝶啶衍生物适用于抑制磷酸二酯酶,因此可用于预防和/或治疗血栓栓塞性疾病、神经退行性疾病、炎症性疾病、哮喘性疾病以及血液肿瘤性疾病。